TCRs targeting differentiation antigens (MART-1, tyrosinase/gp100, CEA) were mostly limited by on-target, off-tumor toxicities to healthy tissues that share antigen expression with the tumor. The gene discussed is CEACAM5; the disease is neoplasm.